ABT-418 hydrochloride

• 产品号: A6476
• CAS号: 147388-83-8
• 分子式: C9H15ClN2O
• 分子量: 202.6812
• 纯 度: ≥98% (HPLC)
• 保 存: desiccated

产品别名

• 标题: ABT-418 hydrochloride
• IUPAC标准名: 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole hydrochloride
• IUPAC传统名: 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole hydrochloride
• 别名: 3-Methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]isoxazole hydrochloride

产品登记号

• PubChem SID: 24724395
• MDL号: MFCD11045960
• CAS号: 147388-83-8

产品性质

• Empirical Formula (Hill Notation): C9H14N2O · HCl
• 纯度: ≥98% (HPLC)
• 外观: powder
• 溶解度: H2O: soluble15 mg/mL
• GHS警示词: Danger
• GHS危险声明: H300-H310-H330
• 欧盟危险性物质标志: 剧毒(Highly toxic) (T+)
• GHS警示性声明: P260-P264-P280-P284-P301 + P310-P302 + P350
• RID/ADR: UN 2811 6.1/PG 2
• 危险公开号: 26/27/28
• 安全公开号: 7/9-22-28-36/37-45
• 保存条件: desiccated
• 联合国危险货物等级: 6.1
• 联合国危险货物编号: 2811
• 联合国危险货物包装类别(PG): 2
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
Neuronal nicotinic acetylcholine receptor agonist with cognition enhancing and anxiolytic activities.
Legal Information
Subject to U.S. Patent No. 5409946 and sold under license from Abbott Laboratories.
Application
ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. ABT-418 hydrochloride has been used to study new therapeutic approaches for the treatment of Alzheimer’s disease.

详细说明 (简体中文)

Biochem/physiol Actions
Neuronal nicotinic acetylcholine receptor agonist with cognition enhancing and anxiolytic activities.
Legal Information
Subject to U.S. Patent No. 5409946 and sold under license from Abbott Laboratories.
Application
ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. ABT-418 hydrochloride has been used to study new therapeutic approaches for the treatment of Alzheimer’s disease.